Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May;50(6):1553-1555.
doi: 10.1007/s00259-023-06177-5.

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Antoine Verger #  1 , Igor Yakushev #  2 , Nathalie L Albert  3 , Bart van Berckel  4 , Matthias Brendel  3 , Diego Cecchin  5 , Pablo Aguiar Fernandez  6 , Francesco Fraioli  7 , Eric Guedj  8 , Silvia Morbelli  9 , Nelleke Tolboom  10 , Tatjana Traub-Weidinger  11 , Donatienne Van Weehaeghe  12 , Henryk Barthel  13
Affiliations
Editorial

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Antoine Verger et al. Eur J Nucl Med Mol Imaging. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AV has received speaker honoraria from GE Healthcare, Curium and Philips.

IY has received consultant and lecture fees from ABX-CRO, Blue Earth Diagnostics, and Piramal.

HB received reader honoraria from Life Molecular Imaging and speaker honoraria from Novartis/AAA.

DC (as PI) received a research grant from Life Molecular Imaging and participated in a research grant offered by Ge Healthcare related to Amyloid PET imaging.

MB received speaker honoraria from Roche, GE healthcare and Life Molecular Imaging and is an advisor to Life Molecular Imaging.

The other authors declares that they have no conflict of interest.

Comment on

  • Lecanemab in Early Alzheimer's Disease.
    van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.

References

    1. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13:80. doi: 10.1186/s13195-021-00813-8. - DOI - PMC - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. doi: 10.1056/NEJMoa2212948. - DOI - PubMed
    1. Planche V, Villain N. US Food and Drug Administration approval of aducanumab—is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol. 2021;78:1307. doi: 10.1001/jamaneurol.2021.3126. - DOI - PubMed
    1. Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease. Alzheimers Res Ther. 2022;14:182. doi: 10.1186/s13195-022-01129-x. - DOI - PMC - PubMed
    1. Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab — binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics 2022. 10.1007/s13311-022-01308-6 - PMC - PubMed